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1. Introduction 
When Auguste Deter died in 1906, Alois Alzheimer, who had closely followed her mental 
degradation over the previous 5 years, obtained her brain and performed a post-mortem study. 
By using a silver-staining method just developed by Bielschowsky, Alzheimer identified 
aggregations of fibrils and what he called ‘miliary foci’. Alterations of that nature had been 
already observed by others in post-mortem brains, but Alzheimer was the first to relate them to 
his patient’s dementia. He described the case a year later and Auguste Deter remained in 
medical history as the first clinical case of what has been ever since referred to as Alzheimer’s 
disease. For an English translation of Alzheimer’s 1907 paper, see (Alzheimer et al., 1995).   
1.1 General description 
Alzheimer’s disease (AD) is an irreversible neurodegenerative disorder, characterized by a 
gradual loss of the cognitive functions inexorably leading to dementia. From an early stage 
characterized by a mild loss of recent memory, the disease advances to more devastating 
symptoms such as faulty judgments and even personality changes, to terminate in a 
complete loss of reasoning ability and self sufficiency. Death normally ensues 8 to 10 years 
after diagnosis.  
AD is often referred to as early- or late-onset depending on whether it appears before or 
after age 65, and is normally distinguished in familial, i.e., inherited, and sporadic, which is 
caused by a combination of genetic, lifestyle and environmental factors. 
About 75% of AD patients have the sporadic form, which has normally a late-onset. The 
familial form, which affects the remaining 25%, can have instead either an early-onset (about 
5% of all familial cases) or a late-onset.  
The early-onset familial AD is attributed to mutations in one of three genes: amyloid 
precursor protein (APP), Presenilin1 or Presenilin2. The genetic causes of the late-onset 
familial AD are not fully assessed, although the inheritance of the ε4 allele of the 
apolipoprotein E (ApoE4) has been recognized as a risk factor for both familial and sporadic 
late-onset AD. Carriers of this allele have a 90% statistical risk of contracting AD if they are 
heterozygote and a virtual certainty if homozygote (Corder et al., 1993).  
www.intechopen.com
 Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets 370 
All forms share the same alterations that include neuron loss, synapse loss, amyloid plaques, 
neurofibrillary tangles and microgliosis. However, although it is well established that AD 
symptoms are due to a compromised neurotransmission originating from these alterations, 
there is not yet full agreement on what actually initiates the neurodegeneration.  
1.2 Diagnosis 
Since no single test or biochemical measurement can securely lead to a diagnosis of AD, 
intellectual deterioration is diagnosed as possible or probable AD on the basis of a careful 
analysis of the symptoms, the medical history of both patient and his/her relatives, a variety 
of neuropsychological tests and from the exclusion of alternative conditions, generally 
attained via neuroimaging. Almost universally physicians today follow the NINCDS-
ADRDA Criteria for diagnosis of Alzheimer’s disease (McKhann et al., 1984), jointly 
published in 1984 by the National Institute of Neurological and Communicative Disorders 
and Stroke and the Alzheimer's Disease and Related Disorders Association, which specify 
eight cognitive domains that are compromised in AD - memory, language, perceptual skills, 
attention, constructive abilities, orientation, problem solving and functional abilities - and 
give guidelines for impairment assessment and diagnosis. NINCDS-ADRDA criteria have 
proven reliable over the years and have been extensively updated in 2007 to account for 
recent advances in neuroimaging (Dubois et al., 2007).     
1.3 Symptoms 
 
Symptom progression of AD 
Function 
Stage I 
 (mild) 
Stage II 
 (moderate) 
Stage III  
(severe) 
Memory 
Mild amnesia 
(recent memory) 
Amnesia 
(recent and 
remote) 
Not measurable 
Language Quasi-normal, anomia Sensory aphasia Severely impaired 
Perceptual skills Mildly  impaired 
Moderately to 
severely impaired 
Not measurable 
Attention Reduced Impaired Not measurable 
Constructive 
abilities 
Reduced Impaired Not measurable 
Orientation Mildly  impaired Impaired Not measurable 
Problem solving Mildly  impaired Impaired Not measurable 
Functional abilities 
Almost normal, 
some mistakes 
Unreliable Not measurable 
Behavior 
Mild changes, 
signs of withdrawal 
Absent 
Agitated,  
delusional 
Gait Normal Normal Impaired 
Posture Normal Normal or flexed Bedridden 
MMSE 25-21 20-11 10-0 
Table 1. Symptom progression of AD; MMSE: Mini-mental state examination (Folstein et al., 
1975). 
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1.4 AD pathology 
1.4.1 Macroscopic pathology 
Atrophy is the major macroscopic characteristic of the AD brain. Ventricles are dilated, gyri 
appear narrower and sulci wider than in a normal brain. The loss of tissue, which roughly 
correlates with the degree of cognitive decline, is so severe that an AD brain can weigh less 
than 1000g. Frontal, parietal and temporal lobes are all involved, the hippocampus in 
particular being severely affected. The primary sensory-motor cortex appears affected with 
some delay, whereas the occipital lobe is relatively spared. 
1.4.2 Microscopic pathology 
The ‘miliary foci’ and fibril aggregations that Alzheimer observed are today normally 
referred to as senile plaques (SPs) and neurofibrillary tangles (NTFs), and remain the 
hallmarks of AD.  
SPs are clusters of protein fibrils that form in the extracellular space, made of an 
amyloidal core, abnormal neurites and glial cells. The amyloidal core is mainly an 
aggregation of Amyloid-beta (Aǃ), a 4 kDa peptide 39 to 43 amino acids long, which is 
produced by the proteolytic cleavage of the APP, a transmembrane protein present in 
many cell types and highly concentrated on neuron synapses. Usually, APP is cleaved on 
the extracellular side of the neuronal membrane by the enzyme ǂ-secretase, but 
occasionally it can be cleaved by two other enzymes (ǃ- and -secretase) at different sites. 
The result is anyway the production of Aǃ segments that are released in the extracellular 
space and aggregate there in amyloidal plaques. The gene for APP is located on the long 
arm of chromosome 21. 
SPs are roughly spherical with a diameter reaching up to 200 µm, and are normally 
distinguished in ‘diffuse’ and ‘compact’: Diffuse SPs are amorphous deposits of non-fibrillar 
‘pre-amyloid’ Aǃ, which produce no alteration of the neuropil. Compact SPs, more often 
referred to as ‘neuritic’, show instead an amyloid core surrounded by dystrophic neuritis. 
The latter appear as clusters of radially oriented neuronal processes.  
There are at least 3 subtypes of neuritic SPs: Primitive, which lack the amyloidal core; 
Classical, in which a dense amyloid core is surrounded by dystrophic neuritis, which in turn 
appear interconnected by low density amyloidal fibrils; Burned-out, which have only the 
dense amyloidal core and at most a few neurites. This subdivision mirrors what researches 
believe is SPs’ evolution: after being released, Aǃ segments forms diffuse plaques in the 
extracellular space until elements such as cytokines, ApoE, proteoglycans and others 
become embedded with the complex causing it to degenerate into neuritic plaques. In other 
words, SPs start as diffuse and then evolve into neuritic, first primitive, then classical, and 
finally burned out. 
SPs appear to have also an anatomical hierarchy: higher-order association areas have the 
highest density of SPs, whereas the primary sensory-motor cortex the lowest. Striatum and 
cerebellum show a rather high density of SPs, but they are all of the diffuse type. The 
hippocampus appears relatively spared.  
Only neuritic SPs are specific to AD, whereas diffuse SPs are found also in the brains of non-
demented elderly individuals. 
NFTs are aggregates of modified protein tau in the intracellular space. In normal conditions, 
the protein tau binds to microtubules, contributes to the progress of their formation and is a 
key element in their stability. In AD, tau undergoes hyper-phosphorylation which causes 
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the protein to aggregate. Moreover, upon hyper-phosphorylation, tau loses its binding 
capability so that the microtubules disintegrate. Each filament is made of two strands 
twisted around each other to form a helix, whose period is about 80 nm and diameter either 
8 nm or 20 nm. 
In AD, the areas most affected by NFTs are hippocampus, sibiculum, amygdala, entorhinal 
and transentorhinal corteces. In the neocortex, higher-order association areas are more 
affected than the unimodal association areas, and the primary sensory-motor cortex is 
relatively spared. NFTs are also numerous in the nucleus basalis, limbic nuclei of the 
thalamus, locus ceruleus, substantia nigra, and the raphe nuclei of the brainstem. 
NFTs’ shapes seem to be influenced by the shape of the neuron in which they are. In fact, 
they look like a flame in pyramidal neurons, as for example in the hippocampus, whereas 
they appear more globular in rounded neurons, such as those of the nucleus basalis. 
NFT develop first into early and then into fully grown tangles. After the death of the neuron 
some NFTs (often referred to as ‘ghost’ tangles) are visible also in the extracellular space. 
It is important to remember, though, that NFTs are not AD specific and are frequent also in 
non-demented elderly individuals.  
Neuropil threads are another form of neurofibrillary degeneration that in AD is found 
widely distributed throughout the gray matter, especially in distal dendrites and axons. 
They owe their name to their appearance which resembles short threads.  
As mentioned above, the ultimate result of the presence of plaques and tangles in AD is a 
severe neuronal loss that can reach 60% in the hippocampus and 80% in the nucleus basalis 
and in some frontal and temporal areas. 
2. Hypotheses on the causes of AD 
2.1 Classic hypotheses 
There are three major classic hypotheses on the origin of AD. The cholinergic hypothesis 
(Francis et al., 1999, Rossor 1983), which is the oldest and the one on which the majority of 
currently available drug therapies are based, proposes that AD is caused by a reduced 
synthesis of the neurotransmitter acetylcholine. The amyloid hypothesis (Hardy & Allsop, 
1991) postulates instead that the fundamental cause of the disease is the deposition of Aǃ, 
which is supported by the evidence that mutations in the gene for APP, which is known to 
cause Aǃ aggregation, are linked to AD. The tau hypothesis, based on a study 
demonstrating that deposition of Aǃ plaques does not correlate well with neuron loss 
(Schmitz et al., 2004), proposes that abnormalities in the tau protein initiate the disease 
cascade. 
Safety and efficacy of more than 500 pharmaceutical treatments are being investigated in 
clinical trials worldwide on the basis of these three hypotheses. In 2008, two separate clinical 
trials showed positive results in modifying the course of the disease in mild to moderate 
AD: one with the metal complexing agent PBT2 (Lannfelt et al., 2008) and one with 
methylthioninium chloride (Wischik, 2008), a drug that inhibits tau aggregation, which 
unfortunately failed to confirm the positive results in its phase III.  
2.2 The metal hypothesis 
Recently, researchers have uncovered an important role played in AD neurodegeneration by 
transition metals via their properties to cause oxidative stress. In fact, copper and iron are 
known to participate in Fenton-type reactions that generate uncontrollable reactive oxygen 
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species (ROS) capable of damaging and destroying molecular and cellular compartments 
(Atwood et al., 2004).  
Authors have widely reported enhanced metal concentrations in specific areas of AD 
patients’ brains, in particular of iron, copper and zinc in cerebrospinal fluid (CSF) (Smith et 
al., 2010), of iron in the basal ganglia (Bartzokis et al., 2000, Bartzokis & Tishler, 2000), and of 
both iron and copper within SPs and NFTs (Good et al., 1992, Lovell et al., 1998). It has been 
also observed that APP possesses selective zinc and copper binding sites which mediate 
redox activity, causing precipitation of Aǃ even at low concentrations (Bush et al., 1994). 
Also Aǃ possesses selective high and low-affinity metal-binding sites. They can bind 
equimolar amounts of copper and zinc but, in conditions of acidosis, copper completely 
displaces zinc from Aǃ (Atwood et al., 2000). Aǃ reduces the metal ions by transferring 
electrons to O2 and generating hydrogen peroxide in the process.  
If on the one hand Aǃ deposition in plaques is an age-dependent phenomenon, on the other 
hand Aǃ production does not appear to increase with age. This seems to indicate that other 
age-dependent changes, as for example changes in metal homeostasis, may play a key role in 
Aǃ transformation and neurotoxicity. Since copper and zinc are both modulators of the 
glutamatergic neurotransmission (Bush & Tanzi, 2008), abnormalities in metal homeostasis can 
have detrimental effects on synaptic processes, such as metal reuptake or storage in the 
synaptic cleft. All this evidence has eventually led to the proposal of a Metal Hypothesis of AD 
(Bush & Tanzi, 2008), which is based on the concept that it is the interaction of Aǃ with specific 
metals, especially copper, that drives AD pathogenesis by promoting aggregation and 
neurotoxicity. By now, this view has become fully accepted and there is general agreement on 
the existence of a link between AD and oxidative stress phenomena triggered by transition 
metals. The Metal hypothesis of AD is now supported by the results of numerous clinical 
studies (Squitti et al., 2006, Squitti et al., 2002a, Squitti et al., 2003, Squitti et al., 2005). 
3. Iron 
3.1 Iron essentiality 
Iron is essential for life. Of the 4-5 grams of iron normally present in a healthy body, about 
2.5 g bind to hemoglobin and are used to promote respiration. Normally iron is absorbed 
from digested food or supplements. Average amounts are 1 mg/day for men, and 1.5–2 
mg/day for women (Institute of Medicine Food and Nutrition Board, 2001). The majority is 
absorbed in the duodenum, where enterocytes of the duodenal lining reduce ferric Fe3+ to 
ferrous Fe2+, which is then transported across the enterocyte's cell membrane into the cell by 
the divalent metal transporter 1 (DMT1). After completing a number of functions, available 
Fe+2 is transported back out of the cell by ferroportin, which is distributed throughout the 
duodenum enterocytes. Hephaestin, a ferroxidase found mainly in the small intestine, 
oxidizes Fe2+ back to ferric Fe3+. At this point Fe+3 binds transferrin, a protein which takes it 
into circulation. Our body does not have a way to excrete iron in excess, so that the latter is 
stored inside another 450 kDa protein, ferritin, which can store up to 4500 atoms of iron per 
molecule (Fleming & Bacon, 2005). 
3.2 Iron toxicity and the role of ceruloplasmin 
Transported by transferrin, Fe3+ reaches the brain’s capillaries and the Blood-Brain-Barrier 
(BBB), which is made of the brain capillary endothelial cells (BCECs) forming the wall of the 
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capillaries. The luminal side of the BCECs presents transferrin receptors that pick up the 
iron-loaded transferrin protein. An endocytosis is initiated and the receptor-transferrin 
complex is internalized into an endosome. Iron remains inside the endosome while the latter 
crosses through the BCEC and reaches the abluminal side. Here the endosome fuses with 
the external membrane, exposing and then releasing Fe3+ to the extracellular interstitial 
space. The apo-transferrin remains attached to the receptor and the two undergo again an 
endocytosis to travel back to the BCEC luminal side, where apo-transferrin is released into 
the capillary blood for re-cycling. 
In the extracellular space, two Fe3+ atoms bind to a passing transferrin molecule, which 
allows iron to reach the vicinity of a neuron. The neuron membrane displays transferrin 
receptors, an endocytosis is again initiated and the receptor-transferrin complex is engulfed 
in an endosome that sinks into the neuron. Differently from the BCECs, though, the neuron 
possesses DMT1s which allow Fe2+ to be released into the neuron’s intracellular space, 
where iron can finally complete its nutritional function. 
Unfortunately, a potentially dangerous outcome of this process is the reduction of iron back 
into Fe2+. Iron is particularly dangerous in this oxidative state since it can easily enter Fenton 
reactions with H2O2:  
 Fe2+ + H2O2 → Fe3+ + ●OH·+ OH−   (1) 
The hydroxyl radical ●OH is the most reactive and vicious of all ROS species. Moreover, the 
above reaction easily proceeds as follows: 
 Fe3+ + H2O2 → Fe2+ + ●OOH + H+  (2) 
Fortunately, the neuron also displays ferroportin molecules on its membrane, which channel 
Fe2+ out into the extracellular space. At this point, a fundamental role in the neuron health is 
played by ceruloplasmin, a protein present on the astrocytic end-foot. In fact, ceruloplasmin 
catalyzes the oxidation of Fe2+ into Fe3+, by way of the following chemical reaction: 
 4 Fe2+ + 4 H+ + O2 → 4 Fe3+ + 2 H2O  (3) 
Therefore, an unbalance of the ceruloplasmin content or efficiency induces iron-dependent 
oxidative damage to brain tissues (Patel et al., 2002). 
Copper can enter exactly the same reactions, passing through Cu2+ to Cu1+ oxidative states. 
This confers to ceruloplasmin a special character as a ‘crosstalk’ factor linking copper to iron 
metabolism, which appears disarranged in AD. 
4. Copper 
4.1 Copper essentiality 
Copper is also an essential nutrient for man and is normally ingested via food, although it 
has been recently proposed that varying degrees of intake originate from drinking water 
piped through copper plumbing (Brewer, 2010). Copper status in the body is regulated by 
both duodenal absorption (intestine) and biliary excretion (liver). After crossing the 
intestinal lumen, copper is transported to the liver via portal circulation. Here, copper is 
partly stored and partly redistributed to other organs. In the hepatocytes, in particular, 
copper is incorporated into ceruloplasmin and into low-molecular-weight compounds, and 
then routed into peripheral circulation or secreted into the bile for excretion. Absorption and 
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excretion interplay in such a way that an occasional over-ingestion in healthy adults 
normally results in a down-regulation of copper uptake in the duodenum and an up-
regulation of biliary excretion. 
4.2 Bound and free copper 
About 85-95% of copper tightly binds to ceruloplasmin, whereas the remainder loosely 
binds to and is exchanged among albumin, ǂ2 macroglobulin, amino acids, peptides and 
several micronutrients. We will refer to the portion that binds to ceruloplasmin as ‘bound’ 
copper, and to the portion that binds to the loose compounds as ‘free’ copper (Linder et al., 
1979), following a custom of Wilson’s Disease clinical care. 
A key difference between bound and free copper lies in the fact that the limited size of the 
low-molecular-weight compounds and the labile nature of their binding allow free copper 
to easily cross the BBB (Chutkow, 1978). A recent study (Choi & Zheng, 2009) has in fact 
shown that the bulk of copper transport into the brain is achieved by free copper ions 
travelling through the BBB, whereas ceruloplasmin-bound copper represents less than 1% of 
the brain bound copper. Normal ranges, within which 95% of the normal population falls 
and which are normally taken as reference values, are 11-22.4 µmol/L for serum copper 
(corresponding to 70-142.7 µg/dL), 20-60 mg/dL for ceruloplasmin, and 0-1.6 µmol/L for 
free copper (corresponding to 10 µg/dL) (Jacobs, 2002).  
It is generally assumed that normal values are ‘healthy’, although some authors suggest 
caution in this regard considering that natural selection works to optimize health and 
survival only during the reproductive period. Consequently, ‘normal’ values may not be 
necessarily optimal after age 50 (Brewer, 2007). In fact, ranges of plasma/serum copper 
values of healthy elderly individuals reported in the literature are very heterogeneous, 
adding complexity in the interpretation of their results (Squitti, 2011).  
4.3 Copper toxicity 
Although copper is an essential nutrient for man, it becomes extremely toxic when its levels 
loose balance. It is a transition metal and as such takes part in a variety of biological reduction 
and oxidation (redox) reactions, which make it an important cofactor of many redox enzymes. 
As mentioned above, copper can easily go into Haber-Weiss and Fenton reactions producing 
●OH (1), against which the body has no defenses (Gutteridge & Halliwell, 1990). An overload 
of this metal can easily lead to oxidative reactions resulting in cell damage and death.  
Moreover, copper absorption and excretion is regulated by mechanisms controlled by 
genetic as well as environmental factors. Therefore, a copper toxicosis is generally the result 
of a failure of one or more of those mechanisms, although sometimes, but infrequently, a 
copper excess may be due to a clinical disease, such a liver cirrhosis. The genetic origin of 
copper toxicosis manifests itself most clearly in the failure to express a specific copper 
transporter, particularly in the liver (see below). Sheep, for example, are easily subject to 
copper toxicosis since they are not able to increase biliary copper excretion in response to an 
increased intake. Conversely, pigs are known to tolerate even severe increases of copper 
intake very well for the opposite reason (Bremner, 1979). However, toxicity per se ultimately 
stems from copper’s ability to catalyze the production of compounds that generate oxidative 
stress, as expressed in reactions (1), (2), (3) detailed above.  
The disruption of the system controlling copper homeostasis has serious consequences for 
the health and development of the brain. This is well exemplified by two genetic disorders, 
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showing either shortage - Menkes’ disease - or excess - Wilson’s disease - of systemic 
copper, but both resulting in neurodegeneration. In these diseases, the genes coding for the 
two membrane copper transport proteins ATPase7A and ATPase7B are mutated. These two 
proteins are highly homologous, but with different patterns of tissue expression: ATPase7A 
(Menkes’ protein) is mainly expressed in the intestine and in the BBB, while ATPase7B 
(Wilson’s protein) is primarily found in the liver (Harris, 2000). The mutation impairs the 
function of the ATPase7A pump and prevents copper absorption at the intestinal level. This 
causes copper deficiency and reduces the levels of cuproenzymes (Harris, 2000). The 
location of ATPase7A at the choroid plexes makes this pump crucial for controlling the 
copper flux into the ventricles of the brain (Qian et al., 1998). Indeed, the copper deficiency 
in the brain of Menkes’ patients is particularly severe because of a decrease in the activity of 
ATPase7A at the BBB. Defects of ATPase7B in Wilson's disease cause impairment of copper 
incorporation into ceruloplasmin, with consequent failure of copper release into the bile 
canalicula for excretion (Iyengar et al., 1988). This produces a copper overload into the 
hepatocytes, inducing liver cirrhosis as well as slight increased levels of free copper. At the 
death of the cirrhotic hepatocytes, copper – actually free copper - is released into general 
circulation in huge amounts and reaches all organs and tissues, including the brain (Choi & 
Zheng, 2009, Hartter & Barnea, 1988, Iyengar et al., 1988). The holo-active form of 
ceruloplasmin depends on the ATPase7B activity, which mediates the incorporation of 
copper atoms into ceruloplasmin during its biosynthesis (Bielli & Calabrese, 2002). 
ATPase7B absence or impairment prevents copper translocation to the secretory pathway, 
resulting in 1) secretion of unstable apo-ceruloplasmin which is rapidly degraded in the 
blood (Bielli & Calabrese, 2002); 2) alteration of copper excretion through the bile via 
ceruloplasmin (Iyengar et al., 1988); 3) severe hypo-function, which can even cause death, of 
hepatocytes; 4) release of free copper in general circulation and tissue copper overload or 
intoxication (Bielli & Calabrese, 2002). During aging, control over copper homeostasis can 
undergo progressive failure and even “normal” copper values could result in an altered 
copper burden in the aged brain (Deibel et al., 1996).  
4.4 Copper chaperones 
Besides the obvious function as means of transportation, chaperones are also the main 
defense system against copper excess. Copper import into the intestinal epithelial cells is 
mediated by the membrane protein Copper transporter protein 1 (Ctr1) (Figure 1) (Kim et 
al., 2008).  
Based on its structural and biochemical properties, Ctr1 could be thought of as a Cu+1-
specific pore. In hepatocytes, intracellular copper is carried by specific chaperone proteins to 
Cu-dependent enzymes. So far, researchers have identified three copper chaperones, 
although new candidates are being investigated: the Human Atox 1 Homologue (HAH1), 
homologous to the yeast Antioxidant protein 1 (Atox1); the Copper Chaperone for 
Superoxide Dismutase (CCS); the Cytochrome C Oxidase Assembly Homologue (COX17). 
HAH1 delivers copper to the two mammalian P-type Cu-transporting ATPases, ATPase7A 
and ATPase7B. CCS delivers copper to the metal-binding site of Copper-Zinc superoxide 
dismutase (Cu,Zn SOD). COX17 delivers copper to the mitochondria, where it is ultimately 
incorporated into the Cytochrome C Oxidase. In a healthy physiological environment, 
virtually no copper remains unbound (Fig. 1) (Kim, et al., 2008). The chaperone system also 
includes metallothioneins, a family of proteins, whose expression is regulated by copper and 
other metals (Palmiter, 1994) and which are active in trapping metals in excess. It has been 
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reported that Metallothionein-3, a member of the family expressed exclusively in the central 
nervous system and involved in neuronal damage repair through its neuro-inhibitory 
activity, is significantly down-regulated in AD (Durand et al.,2010 , Meloni et al., 2008, Yu et 
al., 2001). It was recently proven that this protein protects cultured neurons from toxicity 
generated by Aǃ. A metal swap between Metallothionein-3 and soluble aggregated Aǃ 1–
40–Cu2+ avoids ROS production and consequent cellular toxicity. Finally, Cu,Zn SOD, 
beside its primary antioxidant function of superoxide dismutation,  also plays a role as a 
buffer of intracellular free copper, since it is stable in its copper-free form (Rossi et al., 1994). 
 
 
 
 
 
Fig. 1. Copper is metabolically finely regulated by the organism. Once copper crosses the 
intestinal lumen, it is transported into the liver via portal circulation. In the hepatocytes 
copper is incorporated into ceruloplasmin, other copper proteins and compounds and then 
routed into peripheral circulation or secreted into the bile for excretion. Copper in excess 
from general circulation is excreted through the kidney, in urine. In the hepatocytes, 
intracellular copper is carried by specific chaperone proteins to Cu-dependent enzymes. 
Three copper chaperones have been identified to date: the Human Atox 1 Homologue 
(HAH1), homologous to the yeast Antioxidant protein 1 (Atox1); the Copper Chaperone for 
Superoxide Dismutase (CCS); the Cytochrome C Oxidase assembly homologue (COX17). 
The amyloid precursor protein (APP) is deemed to be a new copper chaperone. 
www.intechopen.com
 Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets 378 
4.5 Copper and A 
Neurodegenerative metallochemistry has developed on the observation that APP possesses 
selective zinc and copper binding sequences (Table 1). These sites mediate redox activity 
and can cause the precipitation of Aǃ under mildly acidic conditions, even at very low 
concentrations (Atwood et al., 1998). Researchers believe that this is what happens in the AD 
brain (Atwood et al., 1998). Moreover, Aǃ reduces the metal ions, producing hydrogen 
peroxide by transferring electrons to O2 (Huang et al., 1999a, Huang et al., 1999b). This 
reduction is the key of Aǃ-induced oxidative stress and toxicity, since hydrogen peroxide is 
a well known pro-oxidant molecule as it triggers Fenton's like reactions (1) (2) that generate 
hydroxyl radicals (see formulas in iron paragraph). 
 
Milestones Key Findings 
The amyloid 
precursor protein 
(APP) is a copper 
protein 
APP has a copper binding domain which reduces Cu(II) to Cu(I) 
and produces oxidative stress (Barnham et al., 2003b, Multhaup et 
al., 1996) 
Depletion of intracellular copper results in a reduction of APP 
gene expression (Bellingham et al., 2004b)  
Zinc and copper 
interactions with 
A 
Zinc rapidly destabilized human A40 solutions, inducing 
tinctorial amyloid formation (Bush et al., 1994) 
A peptide with the sulfur atom of Met-35 oxidized to a sulfoxide 
is toxic to neuronal cells (Barnham et al., 2003a) 
A peptide aggregation is induced by copper binding (Atwood et 
al., 2000) 
A-Cu interaction generates ROS (Huang et al., 1999b, Multhaup 
et al., 1996) 
APP-Cu induced toxicity and oxidative stress in primary neuronal 
cultures, producing neuronal demise (Huang et al., 1999a, White 
et al., 1999a) 
Solubilization of 
native A from AD 
brain, transgenic 
mice and cell 
models by metal 
complexing agents 
Solubilization of A from post-mortem brain tissue was 
significantly increased by the presence of chelators, EGTA, 
N,N,N*,N*-tetrakis(2-pyridyl-methyl) ethylene diamine, and 
bathocuproine (Cherny et al., 1999) 
bis(thiosemicarbazonato) complexes - MII(btsc) examined in 
chinese hamster ovary cells overexpressing APP increased levels 
of bioavailable intracellular copper and zinc but also resulted in a 
dose-dependent reduction of Aǃ levels (Donnelly et al., 2008) 
Cu-dependent 
catalytic conversion 
of dopamine, 
cholesterol, and 
biological reducing 
agents to neurotoxic 
H2O2 in vitro and 
animal models 
Aǃ binds copper and cholesterol, facilitating copper oxidation of 
cholesterol to 7–OH cholesterol and to 4-cholestenone, which are 
extremely toxic to neurons. Cholesterol can catalyse copper-Aǃ 
redox cycling (Opazo et al., 2002, Puglielli et al., 2005) 
Trace amounts of copper given to cholesterol-fed rabbits induced 
accumulation of Aǃ in senile plaques and impaired the animals’ 
learning capability (Sparks et al., 2006, Sparks & Schreurs, 2003) 
Table 2. Milestones of the Evidence of Metal Implication in AD 
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APP binds copper in two domains, one located in the extracellular N-terminal region and 
the other in the C-terminal region within the Aǃ peptide (review in Squitti & Zito, 2009). It 
has been proposed that APP reduces Cu2+ to Cu1+ upon coordination, thus promoting the 
non-amyloidogenic cleavage pathway (Barnham et al., 2003b). The ablation of APP, which is 
normally expressed both in the brain and in a limited number of non-neural tissues as 
platelets, liver, kidney, and heart (Duce et al., 2010, White et al., 1999b) in knockout mice 
models produces metal dishomeostasis in these organs and tissues. APP-depleted knockout 
mice have shown a stunning 80% increase of copper concentrations in the liver and a 40% 
increase in the brain. Recently, Duce et al., (2010) reported that APP ablation causes an iron 
increase of 26% in the brain, 31% in the liver and 15% in the kidney.  
As mentioned above, A is generated from APP cleavage by ǂ-, ǃ- and Ǆ-secretases. ǃ-
secretase (BACE1) cleaves at the N terminus, while Ǆ-secretase cleaves at the C terminus of 
the Aǃ sequence. BACE1 is an aspartic protease and may function as a dimer, whereas Ǆ-
secretase is a complex of presenilin-1/2, Aph1, Pen2, and Nicastrin (Edbauer et al., 2003). It 
was reported that BACE1 modulates APP processing and the release of A by interacting 
with CCS. The concept that copper content can modulate BACE1, i.e. the rate-limiting 
enzyme in the production of A (Angeletti et al., 2005), is supported by the recent evidence 
that copper (Cu2+) and manganese (Mn2+) potently increase the expression of both APP and 
BACE1 in a time- and concentration-dependent manner, whereas zinc (Zn2+), iron (Fe2+) and 
aluminum (Al3+) do not (Lin et al., 2008). In vitro studies have demonstrated that different 
variants of Aǃ (1-40, 1-42) have different affinity for copper, and that higher affinity 
generates higher toxicity (Crouch et al., 2007). The results of recent in vitro studies suggest 
that Cytochrome C Oxidase, and therefore the energy production of the cell, may be one of 
the targets of the Cu-Aǃ toxic effect (Crouch et al., 2005). Conversely, copper plays a role in 
the basal regulation of the APP gene. This has been shown in human fibroblasts over-
expressing ATPase7A, a condition that causes copper intracellular depletion. Depletion of 
intracellular copper in these cells results in significant reduction of APP gene expression 
(Bellingham et al., 2004a, Bellingham et al., 2004b). Moreover, a study of cDNA microarray 
technology demonstrated an up-regulation of APP and of the normal cellular prion protein 
(PrPC) in two genetic models of chronic copper overload mutants – fibroblasts from 
C57BL/6-Atp7aMobr and C57BL/6-Atp7aModap – and in a nutritional model of chronic 
copper overload (Armendariz et al., 2004). 
Overall, this evidence shows that the APP gene harbours a copper response element within 
its promoter, such that copper depletion leads to a marked decrease in APP expression and 
supports the evidence that APP is involved in copper homeostasis as a copper 
detoxification/efflux protein. 
Another line of evidence is the effectiveness of copper and iron chelators in hindering redox 
and toxic activities of A and NTFs, whereas a replacement with those metals fully restores 
those activities (Sayre et al., 2000).  
Regarding genetic risk factors, the ApoE4, which is the only well established risk factor for 
AD, has been demonstrated to interact with copper metabolism at different levels. It has 
been shown that ApoE protein possesses antioxidant properties which depend on ‘bound’ 
copper (Miyata & Smith, 1996, Moir et al., 1999, Sanan et al., 1994). ApoE4 isoform has a 
lower antioxidant power than ApoE2 or ApoE3, and is therefore the least effective in 
protecting neurons from the oxidative damage caused by Aǃ. In fact, absolute and free 
copper concentrations are higher in carriers of the ApoE4 allele than in non-carriers 
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(Gonzalez et al., 1999, Squitti et al., 2002a, Squitti et al., 2007). In addition, the correlation 
between typical electroencephalographic (EEG) spectral abnormalities of the AD brain and 
higher-than-normal serum levels of free copper is stronger in ApoE4 carriers than in non-
carriers (Babiloni et al., 2007b, Zappasodi et al., 2008).  
The level of plasma homocysteine is a risk factor for AD (Babiloni et al., 2007a, Gorgone et 
al., 2009), and it’s known that copper mediates Low-Density Lipoprotein (LDL) oxidation by 
homocysteine (Nakano et al., 2004).  
Aǃ binds copper and cholesterol, facilitating copper oxidation of cholesterol to 7–0H 
cholesterol and to 4-cholestenone (Puglielli et al., 2005), which are extremely toxic to 
neurons (Nelson & Alkon, 2005).  
Trace amounts of copper, well below the levels considered safe for humans, given to 
cholesterol-fed rabbits have induced accumulation of Aǃ in senile plaques and impaired the 
animals’ learning capability (Sparks & Schreurs, 2003). Thus, it appears that cholesterol 
increases Aǃ formation and copper promotes Aǃ aggregation and toxicity. Furthermore, 
cholesterol can catalyze copper-Aǃ redox cycling (Opazo et al., 2002). The results from the 
cholesterol-fed rabbit model have been confirmed in transgenic mice (Sparks et al., 2006) 
and provided the rational for the results of a large community prospective study showing a 
strong correlation between copper intake from a diet rich in saturated and trans fats and 
mental decline (Morris et al., 2006). As a result, serious concerns have been raised about a 
possible relationship between copper overexposure from vitamins or drinking water and 
cognitive disturbances (Brewer, 2010, Bush et al., 2003). The belief that copper toxicity is 
involved in the evolution of cognitive disturbances is also supported by recent 
investigations demonstrating an inverse correlation between cognitive performance and 
serum copper levels in cohorts of healthy aged individuals (Lam et al., 2008, Salustri et al., 
2010a).  
5. Metals in AD: A systemic view 
The link between metals and AD has been traditionally investigated focusing on local metal 
accumulations in specific areas of the brain critical for AD. In this frame, authors have 
reported enhanced iron concentrations in AD brains, both in autopsy brain tissues and in 
CSF (Smith et al., 2010), in the basal ganglia (Bartzokis et al., 2000, Bartzokis & Tishler, 2000), 
and around SPs and NFTs (Good et al., 1992, Lovell, et al., 1998). Altered local 
concentrations of copper (Adlard & Bush, 2006), ceruloplasmin (Castellani et al., 1999, 
Loeffler et al., 1996), transferrin and ferritin (Connor et al., 1992) have been also reported. 
We believe instead that the issue should be approached from the different perspective of 
systemic, rather than local, alterations. Results of many in vivo studies demonstrating 
correlations between abnormalities in metal homeostasis and specific deficits and markers of 
AD suggest that local accumulations should be viewed in a wider systemic alteration.  
5.1 Iron 
Besides of course its own levels in general circulation, typical markers of iron status are the 
levels of transferrin, ceruloplasmin, ferritin, transferrin saturation, together with the H63D 
and C282Y mutations of the HFE gene and transferrin’s C2 polymorphism (TfC2). Since 
these gene variants are often associated with a distress of the liver, the classic liver function 
panel, i.e., albumin, transaminases (aspartate transaminase, AST; alanine transaminase, 
ALT) and prothrombin time, contribute to the picture.   
www.intechopen.com
 Metals Involvement in Alzheimer’s Disease Pathogenesis 381 
In a study of 160 AD patients and 79 healthy elderly controls performed by our laboratory 
(Giambattistelli et al., 2011), we evaluated whether and how all the above listed markers of 
iron and liver status are interconnected. Our study revealed that AD patients have lower 
albumin, longer prothrombin time and higher AST/ALT values than controls, indicating a 
liver distress. Also, transferrin was lower and ferritin higher in AD patients. A multiple 
logistic regression backward analysis performed to evaluate the effects of these biochemical 
variables upon the probability to develop AD revealed that a simple one-unit decrease in 
serum transferrin increases the probability of AD by 80%. A one-unit albumin serum-
decrease reduces the AD probability by 20%, while a one-unit increase of AST/ALT ratios 
generates a fourfold probability increase. The role of genetic mutations is well described by 
the fact that while healthy controls carriers of the H63D mutation showed a normal iron 
status, AD patients carriers of the same mutation showed a panel resembling 
hemochromatosis, i.e., higher levels of iron, lower levels of transferrin and ceruloplasmin. 
This picture was not found in non-carrier AD patients. These results suggest that carrying 
the H63D mutation is not itself sufficient to increase the risk of AD. Rather, it is a synergy 
between iron increase, a condition of liver dysfunction and the genetic mutation that 
appears to increase the probability of developing AD (Giambattistelli et al., 2011). 
In another study, we measured serum levels of iron, ceruloplasmin and transferrin, 
calculated the transferrin saturation and evaluated the activation of the ceruloplasmin-
transferrin (Cp-Tf) system, expressed by the Cp/Tf ratio, in relation to the main cognitive 
and anatomical deficit of AD, namely MMSE and medial temporal lobe atrophy (Squitti et 
al., 2010c). Results demonstrated that the values of ceruloplasmin, peroxides and Cp/Tf, 
besides being elevated, inversely correlated with MMSE scores, while medial temporal lobe 
atrophy positively correlated with Cp/Tf and negatively with serum iron levels. All these 
findings demonstrate that the alterations of iron metabolism that accompany the disease are 
systemic rather than local, and indicate that the role attributed by existing literature to local 
metal accumulations in brain areas critical for AD should be rather viewed in the frame of a 
wider systemic alteration, which could be approached taking into account both circulating 
biochemical markers variations and their genetic makeup. In this line, we recently explored 
the hypothesis that polymorphisms of ATP7B, the gene encoding the protein that controls 
the levels of free copper in the body and whose defects cause Wilson’s disease, have higher 
frequencies in AD than in healthy individuals. Two groups of 190 AD patients and 164 
controls were studied in order to compare the frequency of alleles for these two 
polymorphisms using a ’case-control‘ design. Two polymorphisms previously associated 
with Wilson’s disease - GG genotype in the SNP 2495 A>G (Lys832Arg) (exon 10) and GG in 
c.1216T>G (Ser406Ala) (exon 2) – showed an association with susceptibility to AD (Bucossi 
et al., 2010). These polymorphisms also show a link to non-ceruloplasmin copper levels.  
5.2 Copper 
The existence of systemic copper dysfunctions in AD has been a controversial issue for many 
years. In fact, many studies have reported an increase of circulating copper in AD patients with 
respect to healthy controls (Arnal et al., 2010, Bocca et al., 2005, Gonzalez et al., 1999, Smorgon et 
al., 2004, Squitti et al., 2006, Squitti et al., 2009, Squitti et al., 2002a, Squitti, et al., 2003, Squitti et 
al., 2007, Zappasodi, et al., 2008), many others no variation (Basun et al., 1991, Baum et al., 2010, 
Gerhardsson et al., 2008, Jeandel et al., 1989, Kapaki et al., 1989, Molina et al., 1998, Ozcankaya 
& Delibas, 2002, Snaedal et al., 1998), and two very recent studies even a decrease of copper in 
plasma (Vural et al., 2010) and serum (Brewer et al., 2010) of AD patients. Moreover, the latter 
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two studies are in line with two older studies showing that low plasma copper concentrations 
correlate with clinical worsening in AD, one reporting a copper plasma-decrease in more severe 
vs. less severe patients (Kessler et al., 2006), and the other a direct correlation between low 
plasma copper concentrations and cognitive decline (Pajonk et al., 2005). 
 
 
Fig. 2. Standardized mean difference (SMD) in copper serum level. The square represents 
the SMD between patients and controls. The size of the squares is proportional to the sample 
size of the study, the whiskers represents the 95% confidence interval. The diamond 
represents the pooled estimate based one random effects model, with the centre 
representing the point estimate and the width the associated 95% confidential intervals. 
Recently, we have evaluated these heterogeneous results in a meta-analysis, which has 
analyzed data from all the serum, plasma and CSF studies published since 1983 on AD 
patients, to gain an objective evaluation of whether systemic copper variation are associated 
or not with AD. Meta-analysis is a quantitative method that combines the results of 
independent reports to distinguish between small effects and no effects, random variations, 
variations in sample used or in different analytical approaches. After an initial selection 
based on statistical criteria, data from 21 studies on serum copper and 5 studies on plasma 
copper were merged for a pooled total of 966 AD patients and 831 controls (Bucossi et al., 
2010). The analysis concluded that AD patients have actually higher levels of serum copper 
than healthy controls (Fig. 2). Even though moderate, the assessed copper increase is 
sufficient to unambiguously distinguish AD patients from healthy controls.  
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Plasma data did not allow conclusions because of extremely high heterogeneity, but the 
meta-analysis of the combined serum and plasma studies confirmed higher copper levels in 
AD. The analysis of CSF data, instead, revealed no difference between AD patients and 
controls. Previous results from our laboratory are in line with the meta-analysis outcome. 
When we measured copper, iron, transferrin and copper-enzymes as ceruloplasmin and 
Cu,Zn SOD, together with total hydro-peroxides and total radical-trapping antioxidant 
potential (TRAP) levels in the sera of diverse AD patients cohorts (Rossi et al., 2002, Squitti 
et al., 2006, Squitti et al., 2004, Squitti et al., 2002a, Squitti et al., 2005, Squitti et al., 2007), we 
found that copper, peroxides and Cu,Zn SOD activity (Rossi et al., 2002) were higher, TRAP 
was lower and ceruloplasmin and iron did not differ between AD patients and healthy 
controls. These changes appeared to be specifically referred to the AD patients since they 
were not present in vascular dementia (VAD) patients, with the exception of TRAP that was 
lower in VAD patients in comparison to healthy controls (Squitti et al., 2003).  
Diverse explanations can be advocated to account for the systemic copper abnormalities in 
AD. Inflammation can be one reason. In fact, ceruloplasmin, which accounts for 85-95% of 
circulating copper, is an acute phase reactant, whose levels increase during the 
inflammatory response. In a previous study (Squitti et al., 2005), our laboratory investigated 
whether markers of inflammation in general circulation were abnormal in AD, and showed 
that levels of ceruloplasmin were higher in AD than in healthy controls, though close to the 
significance threshold. However, it was clear that the level of ceruloplasmin increase could 
not account for the pronounced rise of serum copper estimated in the patient sample 
analyzed in that study. In fact, when we performed a deeper analysis by distinguishing 
between bound and free copper, results revealed that the copper increase in our AD patients 
was attributable to this latter fraction (Squitti et al., 2006, Squitti et al., 2009, Squitti et al., 
2005). It must be remembered, though, that free copper abnormalities should be considered 
as an additional rather than alternative explanatory variable of copper disturbances in AD 
(Althaus, 2008, Arnal et al., 2010, Brewer et al., 2010, Hoogenraad, 2007).  
5.3 The role of free copper 
The considerations above support the notion of a fundamental distinction between the 
biochemical properties of bound and free copper.  
The levels of free copper are higher in AD patients than in healthy individuals. One 
ultrafiltration study, aimed at finding filterable free copper in AD sera, has also revealed 
concentrations of free copper 3.7 times higher in AD patients than in controls (Squitti et al., 
2006). Free copper levels correlate with AD main cognitive deficits (Squitti et al., 2006, 
Squitti et al., 2009, Squitti et al., 2004, Squitti et al., 2002a, Squitti et al., 2003, Squitti et al., 
2005), with neuro-anatomical (Squitti et al., 2002a) and electrophysiological changes 
(Babiloni et al., 2007b, Zappasodi et al., 2008), with accepted AD markers (Squitti et al., 2006) 
and with known genetic risk factors, such as ApoE4 (Squitti et al., 2002a, Zappasodi et al., 
2008). Copper systemic abnormalities in AD resemble those observed in Wilson’s disease, 
where the free fraction transported by micronutrients plays a fundamental role, while 
ceruloplasmin appears fragmented. Ceruloplasmin fragmentation, revealed by fragments 
<50 KDa, has been reported in AD patients showing higher-than-normal levels of free 
copper (Squitti et al., 2008). This suggests impairment in the incorporation of copper into the 
protein during the biosynthesis (see the “copper chaperones” section). It must be noted, 
though, that in Wilson’s disease the free copper percentage is much higher than the one 
estimated in AD (Siotto et al., 2010) (Fig. 3). 
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Fig. 3. Free copper in Alzheimer’s disease (AD). The figure shows copper distribution its 
two serum pool - copper bound to ceruloplasmin (CB) and free copper - in healthy controls, 
Wilson’s disease (WD)  and AD patients. 
Ceruloplasmin fragmentation, together with the free copper rise in AD, is a copper systemic 
abnormality that could be the cause or the result of a disturbed hepatocyte function, 
possibly resulting in liver hypo-metabolism. This notion is supported by the results of a 
clinical study by our laboratory which demonstrated that AD patients with no evidence of 
additional pathological conditions – including liver diseases – have higher free copper, 
longer prothrombin time and lower albumin levels than controls matched for age, sex and 
risk factors for cardiovascular diseases and medication intake (Squitti et al., 2007). Very 
recently, we reproduced the same evidence in a bigger cohort of AD associated with iron 
abnormalities (Giambattistelli et al., 2011). The hypothesis that copper, as well as iron (see 
below) in AD, might be related to liver hypofunction linked to APP metabolism at the 
hepatocyte level is strongly supported by the evidence that, in the APP knock-out mouse 
model, the APP ablation causes a massive (80%) copper increase in the liver (White et al., 
1999b). More precisely, it could be speculated that, in this mouse model, a perturbation of 
copper efflux linked to APP at the liver level disrupts normal copper transport, producing a 
reduction of the liver’s efficiency to excrete copper through the bile. This would explain the 
elevated (40%) copper level found in the brain (White et al., 1999b).  A hint towards this 
interpretation comes from another study of ours, in which we estimated - via a clearance 
measure – that about 3% of serum free copper is related to CSF copper increase in AD 
patients, possibly interacting with A (Squitti et al., 2006). This evidence fits very well with 
previous results in a mouse model of brain uptake of radiocopper [67Cu(II)], as also 
confirmed by data of a recent study (Choi & Zheng, 2009). In the [67Cu(II)] mouse model, a 
net brain copper uptake occurs and parallels the free copper increase in the injectate, 
starting from a concentration of Cu(II) of 3.2 ng/mL, corresponding to 0.05 mol/L, much 
lower than the 2.5 mol/L value that we evaluated in clinical studies on AD patients (Squitti 
& Salustri, 2009).  
The belief that there is a direct interaction between copper and A, based on the strong 
negative correlation between free copper in serum and A in the CSF (Squitti et al., 2006), is 
sustained by the negative correlation between copper and A in the CSF found by other 
authors (Strozyk et al., 2009). This evidence is also supported by the fact that copper 
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detectable in the CSF is not ceruloplasmin-bound, but is bound to a not yet identified ligand 
(Que et al., 2008).  
The occurrence of copper increase or decrease in the brain is a debated issue. Some authors 
suggested that there is a decrease in bulk tissue levels in AD brains, and particularly in the 
neocortex (Adlard & Bush, 2006). Loeffer and coworkers (Loeffler et al., 1996) reported instead 
that ceruloplasmin and copper are actually increased in AD. Deibel and coworkers (Deibel et 
al., 1996) and Platin and coworkers (Platin et al., 1987) reported lower levels of copper in the 
amygdala and in the hippocampus of AD brains than controls, however the authors 
determined nanograms of copper on micrograms of weight tissue, instead of nanograms of 
copper on micrograms of proteins present in the sample, and it is known that the AD brain 
tissue has plenty of plaques and not of proteins, so their evaluation at least arises some 
concerns. Religa’s and Squitti’s groups (Religa et al. 2006, Squitti et al., 2007) did not find a 
copper decrease in AD. Also our recent meta-analysis of copper-related literature (Bucossi et 
al., 2010) revealed no difference in CSF copper between AD patients and healthy controls. So 
caution is needed when facing this issue. Seminal studies indicate that copper dyshomeostasis 
in the brain, present in normal aging (Maynard et al., 2002), is substantially more pronounced 
in the aged AD brain (Lovell et al., 1998). In fact, copper levels in the plaque-free neuropil of an 
AD brain are approximately 4 times higher than in the neuropil of a healthy brain, and 
approximately 30% higher in the A plaques than in plaque-free regions.  
Our laboratory has started investigating metal involvement in AD as revealed by systemic 
markers detectable in general circulation, and clinical indices of prognosis or AD 
conversion. In particular, in order to evaluate whether information on iron or copper 
abnormalities can help in the AD prognosis, we assessed levels of copper, iron, zinc, 
transferrin, ceruloplasmin, peroxides, TRAP, free copper and ApoE4 genotype in 81 mild or 
moderate AD patients (Squitti et al., 2009). We studied the association of these wide set of 
parameters with the patients’ scores in the MMSE (primary outcome), in the Activities of 
Daily Living (ADL) and Instrumental of Daily Living (IADL) tests (secondary outcomes), 
performed at study entry and after 1 year. Our study revealed that free copper can predict 
the annual change in MMSE, adjusted for the baseline MMSE: it raised the explained 
variance from 2.4% (with only sex, age and education) to 8.5% (p= 0.026). When the annual 
change in MMSE was divided into <3 or >=3 points, free copper was the only predictor of a 
more severe decline (predicted probability of MMSE worsening 23%). In other words, this 
study showed an association between systemic copper deregulation and unfavorable 
evolution of cognitive function in AD patients, demonstrating that free copper identify those 
patients at higher risk for a more severe decline (Squitti et al., 2009). 
In a very recent study we tested the hypothesis that free copper was increased 
significantly enough to distinguish also individuals affected by mild cognitive 
impairment (MCI) from healthy controls (Squitti et al., 2011). To verify this hypothesis a 
sample of 83 MCI subjects were compared with 100 elderly controls in terms of levels of 
serum copper, free copper, ceruloplasmin, ApoE4, iron, transferrin, and TRAP. The groups 
were compared also in terms of demographic and cardiovascular risk factors. The 
comparison with an additional group of 105 mild to moderate AD patients was also 
evaluated. A multinomial logistic regression analysis demonstrated that ApoE4 and free 
copper differentiated MCI from healthy subjects. Chances to acquire MCI increased about 
24% for each free copper unit (µmol/L) increment. ApoE4 and free copper differentiated 
the MCI group also from the AD group. ApoE4 and free copper appeared associated to 
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MMSE worsening, as did age and sex (Squitti et al., 2011). A follow-up study is in 
progress on MCI subjects, which will test whether free copper can provide information 
about who, within the MCI subjects, will progress to AD. 
In another study we have investigated normal women over age 50 (Salustri et al., 2010a). We 
studied their free and ceruloplasmin bound copper, and measured MMSE and several other 
measures of memory and cognition (19 neuropsychological test battery). We found that free 
(but not ceruloplasmin bound) copper levels correlated inversely with MMSE and certain 
other measures of memory, that is, the higher the free copper, the poorer the performance 
on these measures of cognition.  
Subsequently, we investigated the relationship between depression, which is advocated as a 
risk factor of AD, markers of oxidative stress and neurotransmission, as expressed by 
sensory cortex excitability (Dal Forno et al., 2005, Salustri et al., 2010b). Serum levels of 
oxidative stress markers and somatosensory magnetic fields, evoked by external galvanic 
stimulation, were measured in 13 depressed patients and 13 controls. Depressives had 
higher levels of total and free copper than controls and lower levels of transferrin. They also 
showed lower sensory cortex excitability, which correlated with copper levels in controls, 
but not in depressed patients. Transferrin correlated with sensory cortex excitability in both 
patients and controls, although in opposite ways. Copper level results associated with the 
patients' clinical status. Pro-oxidant compounds appear to affect neuronal excitability and 
clinical state of depressed patients, as free copper excess alters their cortical glutamatergic 
neurotransmission (Salustri et al., 2010a). 
6. Treatment of AD with metal complexing agents 
Since the ‘90s, researchers have cultivated the idea that a tuned redistribution of metals 
(aluminum, iron, selenium, zinc, copper) via metal complexing or ligand agents may 
positively affect the natural progression of AD. Numerous studies have been published 
reporting on tests with metal complexing agents as potential therapeutics for AD (Duce & 
Bush, 2010, Liu et al., 2010, Price et al., 2007), and their pros and cons, as well as the 
challenges associated with their usage, are under debate (Hegde et al., 2009, Squitti & 
Salustri, 2009, Squitti & Zito, 2009). The following is a summary of the most promising 
molecules with metal redistribution properties developed so far, together with a description 
of their potential or proven applications. 
Zinc-induced aggregation of Aǃ can be reversed by the divalent metal ion chelator 
ethilendiamine tetra acetic acid (EDTA)(Huang et al., 1999a). Solubilisation of Aǃ derived 
from AD brains was achieved with N,N,N’,N’-tetrakis (2-pyridylmethyl) ethylene diamine 
(TPEN) and 2,9-dimethyl-4,7-diphenyl-1,10-phenanthroline (bathocuproine) (Cherny et al., 
1999).  Bathocuproine, bathophenahtroline and diethylenetriamine penta-acetic acid (DTPA) 
halted A redox activity complexing copper (Atwood et al., 2004).  
Another metal ligand molecule [1,2-bis(2-aminophenyloxy)ethane-N,N,N’,N’-bis (2-
octadecyloxyethyl) ester,N,N’-disodiumsalt] DP-109 (Lee et al., 2004), was found to reduce 
amyloid plaques and cerebral amyloid angiopathy in Tg2576 mice.   
XH1, a lipophilic amyloid-targeting metal chelator designed with amyloid-binding and 
metal chelating moieties, reduced APP protein expression in human cells and Aǃ pathology 
in APP transgenic mice (Dedeoglu et al., 2004). Similar results were achieved with the 
lipophilic metal chelator DP-109, which markedly decreased A plaques in APP transgenic 
mice (Lee et al., 2004). 
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Ammonium tetrathiomolybdate forms a stable tripartite complex with copper and proteins 
(Squitti & Salustri, 2009). Given with food, tetrathiomolybdate can complex food copper 
with food proteins, making all copper, including the endogenously secreted copper in 
saliva, gastric juice and intestinal secretion completely unabsorbable and thus causing an 
immediate negative copper unbalance. Given instead separate from food, 
tetrathiomolybdate is absorbed into the blood, where it forms the tripartite complex, 
bridging the freely available, and potentially toxic, copper with albumin. This complexed 
copper cannot be taken up by cells, and is therefore non-toxic, it has no known biological 
activity, and is largely cleared in the bile (Squitti & Salustri, 2009). A recent study tested the 
ability of tetrathiomolybdate to reduce A pathology and spatial memory impairment in 
both a prevention and a treatment paradigm in Tg2576 mice. The study demonstrated that 
tetrathiomolybdate lowered brain copper concentrations and reduced A levels in the 
prevention paradigm, but not in the treatment paradigm, suggesting that lowering systemic 
copper may achieve anti-amyloid effects if initiated early in the disease process (Quinn et 
al., 2010). 
Metal bis(thiosemicarbazonato) complexes - MII(btsc), where M stands for either Copper (II) 
or Zinc (II) - can affect extracellular levels of Aǃ.  Treating Chinese hamster ovary cells 
overexpressing APP with engineered MII(btsc) increased levels of bioavailable intracellular 
copper and zinc but also resulted in a dose-dependent reduction of Aǃ levels (Donnelly et 
al., 2008). 
Iron-regulated APP in Aǃ peptide in cell cultures were decreased by (-)-epigallocatechin-3-
gallate, the main poliphenol constituent of green tea (Reznichenko et al., 2006).  It was 
demonstrated that this molecule has metal-chelating and radical-scavenging properties that 
have an effect on iron metabolism in AD. 
Nanoparticles conjugated to chelators were shown to easily cross the BBB, chelate metals, 
and exit through the BBB with their corresponding complexed metal ions (Liu et al., 2010). 
Early studies from this group (Liu et al., 2005) showed that these nanochelators can 
effectively remove iron from tissue of AD brain and also from ferritin.  
Some studies (Lim et al., 2001, Lin et al., 2008) recently demonstrated the potential 
application of curcumin, a commonly used spice extracted by turmeric, as an anti-
inflammatory and anti-oxidant molecule with neuroprotective properties. Some authors 
(Cole et al., 2007) demonstrated its metal chelating and neuroprotectant (Jiao et al., 2006) 
effects. In particular, Lin and coworkers (Lin et al., 2008) demonstrated in PC12 cells that 
this compound has strong effects on APP and BACE1 transcription up-regulation mediated 
by copper. The authors suggest that curcumin might have a combined effect on suppressing 
APP and BACE1 transcriptions, blocking the effect of copper. Due to its multi-functional 
effect new derivates have been created to improve curcumin brain bioavailability. Clinical 
studies are currently in progress to verify whether the use of this natural, non-toxic, 
neuroprotective compound with brain access could offer potential therapeutic benefits 
against neuronal damage. 
Clioquinol (see also below) has been found to reverse the aggregation and redox activity of 
Aǃ (49%) by its low affinity for copper in Tg2576 mice (Cherny et al., 2001).  
6.1 Desferrioxamine 
Desferrioxamine is a hexadentate chelator that does not cross the BBB.  This chelator was 
tested for AD efficacy in a single-blinded study and it was reported to slow the clinical 
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progression of dementia (Crapper McLachlan et al., 1991). The target metal of the study was 
aluminum. Iron was administered together with desferrioxamine throughout the whole trial 
period, with the aim of attenuating the bioavailability of aluminum, but not of iron. A 
generalized decrease of metal concentration was observed which, together with a 
decoppering effect, might have been at the basis of the positive clinical outcome.  
 
Rationale Agent Type of study Outcome 
Induction of a negative metal 
balance throughout the 
whole body, as it happens 
with D-penicillamine or Zinc 
compounds in the treatment 
of Wilson’s disease. 
Desferrioxamine 
One single-blinded 
study 
(Crapper McLachlan et 
al., 1991). 
The clinical progression of 
dementia was reported to 
slow down. 
D-penicillamine 
Prospective, 
randomized, double 
blind, parallel, placebo 
controlled phase II 
clinical trial (Squitti et 
al., 2002b). 
H2O2 levels decreased in a 
group of AD patients with 
respect to both their own 
levels before the treatment 
and the levels of the AD 
patients who had taken the 
placebo 
Studies based on the 
hypothesis that 
solubilization of A plaques 
could be achieved by 
stripping them of their metal 
content or by facilitating the 
delivery of metals into the 
cell 
Clioquinol 
Prospective, 
randomized, double 
blind, parallel, placebo 
controlled phase II 
clinical trial (125-375 
mg/BID over 36 weeks) 
(Ritchie et al., 2003). 
Slowing of the rate of clinical 
decline in a subset of AD 
patients with moderate 
dementia 
PBT2 
Prospective, 
randomized, double 
blind, parallel, placebo 
controlled phase II 
clinical trial (12-week 
treatment) (Lannfelt et 
al., 2008). 
Dose-dependent reduction of 
A concentrations in the CSF 
and positive impact on two 
executive functions. 
Studies based on the 
hypothesis that copper 
supplementation can slow 
AD progression 
Copper 
Prospective, 
randomized, double-
blind, placebo-
controlled phase II 
clinical trial. 
Sixty-eight AD patients 
were given oral copper 
supplementation [Cu-
(II)-orotate-dihydrate; 8 
mg Cu daily, for 12 
months (Kessler et al., 
2008). 
Cu supplementation did not 
change the rate of clinical 
decline.  
Studies based on the 
hypothesis that aluminium 
could cause AD 
Zinc  aspartate 
Preliminary trial with 
zinc  aspartate 
administrated per os and 
i.v. for three to twelve 
months to 10 AD 
patients 
(Constantinidis, 1992). 
Improved memory, 
understanding and 
communication in 8 of the 10 
patients treated. The 2 
patients who did not respond 
to the treatment had been 
given zinc aspartate only per 
os. 
Table 3. Milestones in the Treatment of AD Patients with Metals or Metal Complexing 
Agents 
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The fact that desferrioxamine showed such an effect without crossing the BBB could be 
explained by the induction of a negative metal balance throughout the whole body, as it 
happens with D-penicillamine, Zinc compoundsor ammonium tetrathiomolybdate  in the 
treatment of Wilson’s disease. 
6.2 D-penicillamine 
D-penicillamine has been widely used for treatment of Wilson’s disease. It functions as a 
copper chelator, controlling both the reactivity and bioavailability of that metal, ultimately 
facilitating its disposal through the urine. However, adverse events have been reported 
which have drastically limited its use.  
A study of D-penicillamine tolerability and efficacy in the treatment of AD had to be 
interrupted before finishing recruitment, due to a number of serious adverse events (Squitti 
et al., 2002b). Some conclusions were drawn from the patients who had completed the 
treatment at the moment of interruption (18 patients out of 34). Serum and urine copper 
were measured together with red blood cells Cu,Zn SOD (Squitti et al., 2002b, Rossi et al., 
2002). While serum copper had remained stable, urine copper levels were drastically 
elevated, indicating that large amounts of copper were indeed being removed from the 
tissues. Cu,Zn SOD activity was drastically reduced, revealing that this enzyme could be 
used as an indicator of general depletion of bioavailable copper. A significant reduction was 
also observed in the hydroperoxide levels.  
Despite the positive effect in decreasing the bioavailable copper and the content of 
hydroperoxides, the clinical relevance of those results could not be fully assessed because of 
the short duration (24 weeks) of the observation, during which patients in the placebo arm 
did not worsen, precluding the detection of cognitive differences between the treated and 
the placebo groups. Crapper McLachlan and colleagues (Crapper McLachlan, et al., 1991) 
have shown a positive effect of chelation therapy in AD by treating patients for a 24-month 
period, and Ritchie and coworkers (Ritchie et al., 2003) reported some positive results with 
clioquinol (see below) after 36 weeks.    
6.3 Iodochlorhydroxyquin (clioquinol) drug class 
In the early 2000s, clioquinol was tested in man revealing that a treatment of just 21 days 
resulted in a significant improvement of patients’ cognitive performance (Regland et al., 
2001). This study was followed by a case report on two AD patients showing that clioquinol 
could ameliorate focal cerebral glucose metabolism and halt clinical deterioration (Ibach et 
al., 2005), and by a double-blind placebo-controlled clinical trial, in which 36 patients were 
treated with 125 mg/day for the first 12 week, then 250 mg/day between week 13 and 24 
and finally 375 mg/day in the latest period of weeks 25-36 (Ritchie et al., 2003). The trial 
revealed that clioquinol slowed the rate of clinical decline in a subset of AD patients having 
more severe dementia. However, in the subgroup of patients with moderate dementia the 
difference between clioquinol and placebo did not reach statistical significance. In addition, 
in this subgroup the drug had no significant effects on the plasma Aǃ levels. 
As stated by the authors, the results of the clioquinol study supported a proof of concept in 
humans that a drug targeting Aǃ-metal interaction can have a significant effect on slowing 
the progression of AD.  
Clioquinol is capable of crossing the BBB, and it is believed that it solubilizes Aǃ plaques by 
stripping them of their metal content. However, after in vitro investigations, it is unclear 
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whether the positive results shown by the clinical trial were related to an attenuated Aǃ-
metal ion interaction or to some other mechanisms.  
In the end, the relevance of the clioquinol conclusions has been severely questioned (Hegde 
et al., 2009). Arguments against the chelating effectiveness of clioquinol referred mostly to 
the evidence coming from a study by Treiber and co-workers (Treiber et al., 2004), who, by 
using a yeast model system, demonstrated that the addition of clioquinol to the culture 
drastically increased copper concentration within the yeast cells. Thus, they attributed the 
positive effects of clioquinol on AD patients to an increase of copper uptake into the neural 
cell, instead of an attenuated Aǃ-metal ion interaction outside the cell. However, the authors 
(Treiber et al., 2004) did not report information about the bioavailability of the intracellular 
copper-clioquinol complex.  
Some information to this regard could be found in a subsequent study demonstrating a 
decreased intracellular metal bioavailability linked to the accumulation of soluble A 
outside the cell (White et al., 2006). Clioquinol, by facilitating the delivery of metals (copper 
and zinc, but not iron) into the cell, seemed to activate the phosphoinositol 3-kinase 
mediated protein kinase pathways, ultimately leading to an increase in the secretion of 
matrix metalloproteinases, which can degrade A outside the cell. This is why molecules of 
the clioquinol drug class have been defined as metal protein attenuating compounds 
(MPAC), and have been attributed both chelating and  ionophoretic properties.  
Establishing the exact localization of clioquinol within the cell, or the copper biovailability of 
the putative clioquinol derivates-copper-complex, could be of help to define the molecular 
mechanisms either triggered or prevented by this class of molecules. Further clioquinol 
phase II/III studies were stalled by difficulties in preventing di-iodo 8-hydroxy quinoline 
contamination upon large-scale chemical synthesis, as well as its citotoxicity profile. In the 
end, clioquinol was withdrawn from human experimentation.  
New compounds were then developed, such as PBT-2, a second-generation compound of 
the clioquinol drug class, that lacks iodine. PBT-2 has been recently tested on AD patients in 
a phase II, double-blind, randomized, placebo-controlled 12 week trial. 74 patients 
completed the trial and well tolerated the 250 mg of PBT-2 daily dosage. This study revealed 
that PBT2 induced a significant dose-dependent reduction of Aǃ concentrations in the CSF, 
even though no drug effects on either Aǃ40 or Aǃ42 plasma levels were detected. Moreover, 
PBT-2 was found to preserve two executive functions, as evaluated via category fluency and 
trail making tests (Adlard et al., 2008, Lannfelt et al., 2008). This promising MPAC is now 
been tested in a phase III clinical trial.  
6.4 Zinc therapy 
Some agents used in anti-copper therapies are specifically aimed at maintaining a state of 
copper malabsorption (Squitti & Zito, 2009).  Zinc acetate and other zinc salts, such as zinc 
carbonate, zinc sulfate, zinc gluconate, zinc oxide, zinc chloride and zinc stearate, are currently 
used in the treatment of Wilson’s disease (Squitti & Zito, 2009). Zinc antagonizes the absorption 
of copper in the gut by increasing metallothioneins concentrations in the mucosa up to 25 times.  
The liver is the main human storage place for copper and metallothioneins are the major copper 
binding proteins in this organ.  Diffusible free copper present in the blood is sequestered in a 
non-toxic form in the mucosal cells lining the intestine by metallothioneins.  In this form copper 
is then excreted with the stools. The copper body balance becomes negative within 2 weeks 
when zinc sulphate is administrated in a dose of 600 mg/day. The safety and positive effects 
shown by zinc compounds, such as zinc sulphate or aspartate, in treating Wilson’s disease 
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strongly recommend the testing of these compounds in AD. Encouraging results in this 
direction were obtained in a preliminary study by Constantinidis (Constantinidis, 1992), who 
reported improvements in memory, understanding, communication, and social contact in eight 
out of ten AD patients treated with zinc compounds.   
6.5 Side effects of anti-copper complexing agents 
The side effects of anti-copper complexing agents and MPAC are primarily limited to 
anemia and leucopenia, due to bone marrow depletion of copper, and occasionally to liver 
toxicity. The frequency of occurrence of these effects shows a correlation with dose strength 
and frequency of drug assumption. For ammonium tetrathiomolybdate, a relatively new 
copper-lowering agent, these events have been associated with the reduction of serum 
ceruloplasmin levels, which is assumed to be a marker of copper defective bioavailability. 
For example, at ceruloplasmin concentrations of 5 mg/dL or less, bone marrow suppression 
is common; it is somewhat frequent at concentrations between 5 and 10 mg/dL, it is only 
occasional between 10-18 mg/dL, and very rare above 18.  
Clioquinol usage in humans has been halted as it has been related with subacute myelo-
optic neuropathy.  
Zinc compounds have only minor adverse events, limited to gastrointestinal troubles. 
7. Conclusion 
The results of the studies described in this chapter should be regarded as single pieces of a 
complex mosaic of systemic disarrangements which result in severe neurodegeneration via 
a variety of biochemical phenomena, among which oxidative stress plays a leading role. In 
this view, systemic metal abnormalities, even if mild but over a long period of time, have 
disrupting effects on central processes controlling the defenses against metal-induced 
damage. Glutamatergic synapses definitely represent focal sites where the metal-A toxic 
action can be promoted resulting in Aǃ precipitation (Bush et al., 2003, Bush & Tanzi, 2008). 
The identification in AD of a free copper serum-level increase, as well as of disturbances of 
iron homeostasis and the activation of the antioxidant Cp-Tf system, appear coherent with 
this picture. Not only can free copper cross the BBB and enter reactions promoting A 
toxicity, but it can systemically activate the Cp-Tf system, promoting iron subtraction from 
general circulation and its consequent internalization into neural cells. Both pathways 
converge towards neurodegeneration and neuronal death. In this framework, properly 
tuning the redistribution of metals via molecules which induce or maintain a state of copper 
malabsorption, such as zinc compounds or metal complexing agents, may possibly have a 
positive effect on the natural progression of AD.  
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